Valneva SE says it expects a positive recommendation from the European Medicines Agency for its adjuvanted inactivated whole virus Covid-19 vaccine for adults aged 18-55 by April 2022.
The company reported on Friday 11 March that its SARS-CoV-2 vaccine candidate (VLA2001) is still under review by the European Medicines Agency’s Committee for Medicinal Products for Human Use, with a review date of 2 December 2021.
The EMA will need to be satisfied with the ongoing review of the vaccine...